We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cel... Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia. Show more
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity PR Newswire NEW YORK, May 15, 2024 - KOL and principal...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older...
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024...
Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern PR...
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European...
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral...
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy PR Newswire NEW YORK, March 26, 2024 Potential...
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand PR Newswire NEW YORK...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.18 | -2.14285714286 | 8.4 | 8.68 | 7.85 | 189071 | 8.23642178 | CS |
4 | -0.73 | -8.15642458101 | 8.95 | 10.24 | 7.85 | 287775 | 9.05791102 | CS |
12 | 0.61 | 8.01576872536 | 7.61 | 10.24 | 6.16 | 403693 | 8.48382866 | CS |
26 | 3.99 | 94.3262411348 | 4.23 | 10.24 | 4.14 | 298366 | 7.50713702 | CS |
52 | 0.32 | 4.05063291139 | 7.9 | 10.24 | 4 | 246766 | 7.11607509 | CS |
156 | -0.2 | -2.37529691211 | 8.42 | 15.12 | 4 | 302291 | 8.10636807 | CS |
260 | 7.9212 | 2651.00401606 | 0.2988 | 15.12 | 0.1506 | 1813269 | 1.44454044 | CS |
Symbol | Price | Vol. |
---|---|---|
NVOSNovo Integrated Sciences Inc | $ 1.0205 (126.27%) | 230.37M |
GWAVGreenwave Technology Solutions Inc | $ 0.0408 (-2.86%) | 190.43M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.54 (-4.48%) | 156.11M |
CRKNCrown Electrokinetics Corporation | $ 0.100899 (-11.10%) | 98.64M |
SQQQProShares UltraPro Short QQQ | $ 10.505 (4.84%) | 82.23M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions